Posts

ESMO Revises Early Prostate Cancer Diagnosis and Monitoring

Image
ESMO Revises Early Prostate Cancer Diagnosis and Monitoring ESMO Issues Major Update to Prostate Cancer Diagnosis and Treatment Guidelines BLUF (Bottom Line Up Front): The European Society for Medical Oncology has released updated clinical practice guidelines that fundamentally change how prostate cancer is diagnosed and monitored, emphasizing safer biopsy procedures, precision imaging before tissue sampling, and aggressive early treatment for high-risk biochemical recurrence. The new recommendations prioritize multiparametric MRI before biopsy, mandate the safer transperineal biopsy approach, and introduce combination androgen deprivation therapy with enzalutamide for patients with rapidly rising PSA after initial treatment—even without visible metastases. A Paradigm Shift in Prostate Cancer Care The European Society for Medical Oncology (ESMO) has comprehensively revised its clinical practice guidelines for localized prostate cancer and biochemical recurrence, representing one of...
Post a Comment
Read more

Active Surveillance for Prostate Cancer:

Image
Current Opinion in Urology A Proven Strategy Gains Ground BLUF (Bottom Line Up Front): Active surveillance has evolved from a controversial "watch and wait" approach into the gold standard treatment for low-risk prostate cancer, with mounting evidence supporting its expansion to carefully selected intermediate-risk patients. Recent research confirms that properly monitored men can safely defer treatment for years—or even indefinitely—while maintaining excellent cancer control outcomes and avoiding the significant side effects of immediate surgery or radiation. From Skepticism to Standard of Care Just two decades ago, most men diagnosed with prostate cancer faced an immediate choice: surgery or radiation. The notion of deliberately monitoring cancer without treating it seemed counterintuitive, even dangerous. Today, active surveillance represents one of the most significant paradigm shifts in prostate cancer management. "Active surveillance is considered the treatmen...
Post a Comment
Read more

5 Tesla MRI Delivers Sharper Prostate Cancer Images Revealing More Cancers

Image
5 T versus 3 T MRI for prostate cancer: an intra-individual prospective comparison of image quality and diagnostic performance | Prostate Cancer and Prostatic Diseases But $10 Million Price Tag Raises Questions About Clinical Value BLUF (Bottom Line Up Front): A January 2026 study shows ultra-high-field 5 Tesla MRI scanners detect prostate cancer more accurately than standard 3 Tesla systems, with 67% stronger signals producing clearer tumor boundaries and better visualization of critical anatomy. However, with fewer than ten 5T scanners worldwide, $7-10 million price tags versus $2-3 million for 3T systems, and questions about whether improved images translate to better patient outcomes, the technology faces a long road from laboratory breakthrough to routine clinical care. The Promise: Significantly Better Images Researchers at West China Hospital of Sichuan University directly compared both technologies in 67 consecutive patients with suspected prostate cancer, having each man u...
Post a Comment
Read more

Prostate Cancer Screening:

Image
What PSA test reliance gets wrong about prostate cancer treatment | STAT Navigating the Balance Between Early Detection and Overtreatment BLUF (Bottom Line Up Front) Prostate cancer screening remains one of medicine's most contentious debates. While PSA testing can detect cancer early and save lives, it also leads to substantial overdiagnosis and overtreatment of slow-growing cancers that may never cause harm. Recent research confirms that approximately 450 men must undergo repeated PSA screening to prevent one prostate cancer death, while the majority of men diagnosed with low-risk disease can safely pursue active surveillance rather than immediate treatment. International practice varies dramatically—with U.S. physicians treating about 40% of low-risk cases compared to under 10% in the U.K.—reflecting different medical cultures and financial incentives. New AI-assisted diagnostic tools and better risk stratification methods are emerging to help distinguish dangerous cancers fro...
Post a Comment
Read more

UCLA Health Andromeda Trial Compares Alpha v Beta PSMA Radioligand Therapies for Recurrent Prostate Cancer

Image
UCLA Health Launches ANDROMEDA Trial Testing Dual PSMA-Targeted Radiopharmaceuticals in Recurrent Prostate Cancer BLUF (Bottom Line Up Front): UCLA Health has initiated the ANDROMEDA trial, the first head-to-head comparison of two PSMA-targeted radioactive therapies—lutetium-177-PSMA-617 (Pluvicto) and the investigational actinium-225-PSMA-617—combined with precision radiation for men with oligorecurrent prostate cancer. This landmark Phase 2 study builds directly on the successful LUNAR trial results and could help determine which radioligand therapy works best for early recurrence while potentially delaying or avoiding hormone therapy and its associated side effects. A New Frontier in Precision Cancer Treatment For men facing prostate cancer recurrence after initial treatment, the ANDROMEDA trial represents a significant milestone in precision medicine. Launched by UCLA Health's Jonsson Comprehensive Cancer Center under the leadership of Dr. Jeremie Calais , this Phase 2 cli...
Post a Comment
Read more